July 3, 2025 06:42 AM EDTUpdated 10:28 AM
Pharma
FDA+

Dizal’s lung can­cer pill ap­proval sets up com­pe­ti­tion with J&J

Elizabeth Cairns

Senior biopharma journalist

Dizal said that its EGFR in­hibitor sun­voz­er­tinib has been ap­proved by the FDA for cer­tain types of lung can­cer.

The pill, now brand­ed as Zegfrovy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Sage talked to 43 'coun­ter­par­ties' be­fore ink­ing Su­per­nus deal

Num­ber of megarounds drop 38% in first half as biotechs strug­gle against wors­en­ing slump

4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

A service from the Financial Times